Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Lorenza Rimassa
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Lorenza Rimassa
168 views
September 20, 2024
Comments 0
Login to view comments.
Click here to Login